View in EDS

Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson.

Saved in:
Bibliographic Details
Title: Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson.
Authors: Lim JU; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea., Lin HY; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kang L; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Le H; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tang TY; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Champiat S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Dumbrava EE; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Le X; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Naing A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Piha-Paul SA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ahnert JR; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tsimberidou AM; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yap TA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fu S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hong DS; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. dshong@mdanderson.org.
Source: NPJ precision oncology [NPJ Precis Oncol] 2026 Jan 13; Vol. 10 (1), pp. 59. Date of Electronic Publication: 2026 Jan 13.
Publication Type: Journal Article
Journal Info: Publisher: Springer Nature Country of Publication: England NLM ID: 101708166 Publication Model: Electronic Cited Medium: Print ISSN: 2397-768X (Print) Linking ISSN: 2397768X NLM ISO Abbreviation: NPJ Precis Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41530472
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Lim+JU%22">Lim JU</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Lin+HY%22">Lin HY</searchLink>; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Kang+L%22">Kang L</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Le+H%22">Le H</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Tang+TY%22">Tang TY</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Champiat+S%22">Champiat S</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Dumbrava+EE%22">Dumbrava EE</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Le+X%22">Le X</searchLink>; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Naing+A%22">Naing A</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Piha-Paul+SA%22">Piha-Paul SA</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Ahnert+JR%22">Ahnert JR</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Tsimberidou+AM%22">Tsimberidou AM</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Yap+TA%22">Yap TA</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Fu+S%22">Fu S</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Meric-Bernstam+F%22">Meric-Bernstam F</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Hong+DS%22">Hong DS</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. dshong@mdanderson.org.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101708166%22">NPJ precision oncology</searchLink> [NPJ Precis Oncol] 2026 Jan 13; Vol. 10 (1), pp. 59. <i>Date of Electronic Publication: </i>2026 Jan 13.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Nature%22">Springer Nature </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101708166 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Print <i>ISSN: </i>2397-768X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222397768X%22">2397768X </searchLink><i>NLM ISO Abbreviation: </i>NPJ Precis Oncol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41530472
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41698-025-01261-5
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 59
    Titles:
      – TitleFull: Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Lim JU
      – PersonEntity:
          Name:
            NameFull: Lin HY
      – PersonEntity:
          Name:
            NameFull: Kang L
      – PersonEntity:
          Name:
            NameFull: Le H
      – PersonEntity:
          Name:
            NameFull: Tang TY
      – PersonEntity:
          Name:
            NameFull: Champiat S
      – PersonEntity:
          Name:
            NameFull: Dumbrava EE
      – PersonEntity:
          Name:
            NameFull: Le X
      – PersonEntity:
          Name:
            NameFull: Naing A
      – PersonEntity:
          Name:
            NameFull: Piha-Paul SA
      – PersonEntity:
          Name:
            NameFull: Ahnert JR
      – PersonEntity:
          Name:
            NameFull: Tsimberidou AM
      – PersonEntity:
          Name:
            NameFull: Yap TA
      – PersonEntity:
          Name:
            NameFull: Fu S
      – PersonEntity:
          Name:
            NameFull: Meric-Bernstam F
      – PersonEntity:
          Name:
            NameFull: Hong DS
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 13
              M: 01
              Text: 2026 Jan 13
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-print
              Value: 2397-768X
          Numbering:
            – Type: volume
              Value: 10
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: NPJ precision oncology
              Type: main
ResultId 1